폐경 여성에서 3년 동안 호르몬 요법, 랄록시펜, 알렌드로네이트 치료 후 혈청 지질과 체질량 지수의 변화

키워드

참고문헌 (40)

1. Hulley S, "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen", progestin Replacement Study (HERS) Research Group, 1998, pp.280, 605~613
2. Grady D, "Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen", progestin Replacement Study follow-up (HERS II), 2002, pp.288, 49~57
3. Herrington DM, "Effects of estrogen replacement on the progression of coronary-artery atherosclerosis", N Engl J Med, 343, pp.522~529 (2000)
4. Magliano DJ, "Hormone therapy and cardiovascular disease: a systematic review and meta-analysis", BJOG, 113, pp.5~14 (2006)
5. Prentice RL, "Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease", Am J Epidemiol, 163, pp.589~599 (2006)
6. Rossouw JE, "Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause", JAMA, 297, pp.1465~1477 (2007)
7. Cosman F, "Selective estrogen receptor modulators: clinical spectrum", Endocr Rev, 20, pp.418~434 (1999)
8. Riggs BL, "Selective estrogenreceptor modulators -- mechanisms of action and application to clinical practice", N Engl J Med, 348, pp.618~629 (2003)
9. Delmas PD, "Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women", N Engl J Med, 337, pp.1641~1647 (1997)
10. Vogel VG, "Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial", JAMA, 295, pp.2727~2741 (2006)
11. Grady D, "Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation", Obstet Gynecol, 104, pp.837~844 (2004)
12. Barrett-Connor E, "Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women", N Engl J Med, 355, pp.125~137 (2006)
13. Barrett-Connor E, "Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial", JAMA, 287, pp.847~857 (2002)
14. Tankó LB, "Relationship between osteoporosis and cardiovascular disease in postmenopausal women", J Bone Miner Res, 20, pp.1912~1920 (2005)
15. Yamaguchi T, "Plasma lipids and osteoporosis in postmenopausal women", Endocrinol J, 49, pp.211~217 (2002)
16. van Beek ER, "Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates", Bone, 33, pp.805~811 (2003)
17. Guney E, "Effects of bisphosphonates on lipid metabolism", Neuro Endocrinol Lett, 29, pp.252~255 (2008)
18. 주일우, "Alendronate 10 mg을 2년간 투여한 한국 폐경 여성에서의 혈청 지질 수치 변화 -대조군 비교 연구-", Endocrinology and Metabolism, 22(1), pp.19~25 (2007), 대한내분비학회
19. Adami S, "Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol", J Bone Miner Res, 15, pp.599~604 (2000)
20. Walsh BW, "Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins", N Engl J Med, 325, pp.1196~1204 (1991)
21. Binder EF, "Effects of hormone replacement therapy on serum lipids in elderly women. a randomized, placebo-controlled trial", Ann Intern Med, 134, pp.754~760 (2001)
22. Ottosson UB, "Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone", Am J Obstet Gynecol, 151, pp.746~750 (1985)
23. The Writing Group for the PEPI trial, "Effects of estrogen or estrogen", progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen, JAMA, pp.1995, 273[DOI]
24. Davidson MH, "Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women", Arch Intern Med, 160, pp.3315~3325 (2000)
25. Godsland IF, "Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000", Fertil Steril, 75, pp.898~915 (2001)
26. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
27. Anderson GL, "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial", JAMA, 291, pp.1701~1712 (2004)
28. Manson JE, "Clinical practice. Postmenopausal hormone-replacement therapy", N Engl J Med, 345, pp.34~40 (2001)
29. Hodis HN, "Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial", Ann Intern Med, 135, pp.939~953 (2001)
30. Manson JE, "Estrogen plus progestin and the risk of coronary heart disease", N Engl J Med, 349, pp.523~534 (2003)
31. Hsia J, "Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative", Arch Intern Med, 166, pp.357~365 (2006)
32. 23rd North American Menopause Society annual meeting, "KEEPS Report", ~
33. Delmas PD, "Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women", N Engl J Med, 337, pp.1641~1647 (1997)
34. Stampfer MJ, "Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence", Prev Med, 20, pp.47~63 (1991)
35. Collins P, "Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors", Circulation, 119, pp.922~930 (2009)
36. Rodan GA, "Bisphosphonates: mechanisms of action", J Clin Invest, 97, pp.2692~2696 (1996)
37. Dunford JE., "Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition", Curr Pharm Des, 16, pp.2961~2969 (2010)
38. Jun Iwamoto, "Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis", Yonsei Medical Journal, 49(1), pp.119~128 (2008), 연세대학교의과대학
39. Fiore CE, "Bisphosphonates and atherosclerosis", J Endocrinol Invest, 32(4 Suppl), pp.38~43 (2009)
40. Jensen LB, "Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study", J Bone Miner Res, 18, pp.333~342 (2003)

관련 논문AI추천